Suven Life Sciences in demand on Alzheimer drug deal
Shares of Suven Life Sciences touched a 52-week high after the firm said it was in talks with four global pharmaceutical firms, which have shown an interest in outlicense deals for SUVN-502, its lead drug candidate for Alzheimer's disease.
By ET Bureau |
MUMBAI: Shares of Suven Life Sciences touched a 52-week high after the firm said it was in talks with four global pharmaceutical firms, which have shown an interest in outlicense deals for SUVN-502, its lead drug candidate for Alzheimer's disease.
However, the size of deal would be known only after the completion of due diligence around December 2009, media reports suggest.
The stock surged on heavy volumes rising nearly 20 per cent. Shares of the company were trading at Rs 30.55, higher by 15.94 per cent on the BSE.
However, the size of deal would be known only after the completion of due diligence around December 2009, media reports suggest.
The stock surged on heavy volumes rising nearly 20 per cent. Shares of the company were trading at Rs 30.55, higher by 15.94 per cent on the BSE.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
